Search »
- Use quotation marks (e.g., "RSR Manual") to search for exact phrases.
- You must be logged in to search for people in the Ryan White/TargetHIV community.
Content type
Topic Areas
Source
Publication Date
-
-
Ryan White Part A-F Awards Announced for FY21
From the HRSA HIV/AIDS Bureau Update: Special Bulletin - 10/5/21
News Article updated on 10/06/2021 -
Early Intervention Services and Outreach
The Oregon Health Authority awarded contracts to local public health authorities across the state to work with community partners to integrate early intervention services and outreach services, link people to HIV care, and provide support to help clients reach viral suppression. Quick linkage to care resulted in a median of 57 days to viral suppression for Early Intervention Services and Outreach clients in 2019.Resource from the RWHAP Best Practices Compilation updated on 05/14/2024
-
Use of CARES Act Funds and Vaccine Incentives
A new FAQ has been added to the HRSA HIV/AIDS Bureau's Coronavirus Disease 2019 (COVID-19) Frequently Asked Questi
News Article updated on 08/31/2021 -
HIV Services Delivered by HRSA Health Centers, 2020
A significant proportion of people with HIV in the U.S.
News Article updated on 09/02/2021 -
Hybrid Format for Ryan White 2022
Next year’s Ryan White Conference will adopt an in-person/virtual format, while the Clinica
News Article updated on 10/15/2021 -
Rapid ART: An Essential Strategy for Ending the HIV Epidemic
What HIV care providers can do to create a rapid ART program to get HIV clients on treatment the same day as a diagnosis.Resource updated 09/19/2023
-
HRSA Funding Opportunity: HIV Prevention for Health Centers
-
Rapid ART Playbook Outlines Steps to Implementation
Guide on implementing rapid ART the administration of antiretroviral therapy (ART) as quickly as possible and ideally on the same day as an HIV diagnosis/clinic visit.Blog updated 03/03/2022
-
TAP-in EHE Webinar Series
Recordings of the TAP-in webinars on topics critical to the Ending the HIV Epidemic Initiative.Resource updated 05/23/2023
-
HRSA Revises RWHAP Policy Notice on Eligibility Determinations
In October 2021, HRSA's HIV/AIDS Bureau revised its client eligibility and recertification policy for the Ryan White HIV/AIDS Program.
News Article updated on 11/02/2021 -
Responding to an HIV Cluster or Outbreak: Who do you call? What do you do?
Model approaches for community partner engagement and coordination to support interventions for the mitigation of HIV outbreaks.Resource updated 04/07/2023
-
RWHAP CARES Act Expenditures Report
How to access the RWHAP CARES Act Expenditures Report and instructions on CARES Act Expenditures Reporting.Resource updated 12/22/2023
-
HRSA Releases New Fact Sheets on RWHAP Clients
Ten fact sheets on client populations getting care from the Ryan White HIV/AIDS Program (RWHAP) a
News Article updated on 06/30/2021 -
Use of Social Media and Mobile Technology as Essential Tools for EHE
Strategies to engage hard-to-reach youth and young adults through use of social media and related technologies.Resource updated 03/15/2023
-
Performance Measurement: Using Data to Achieve EHE Goals
The use of performance measures to help achieve EHE plan goals.Resource updated 04/07/2023
-
Reviewing the RWHAP Program Terms Report/Allocations Report for Project Officers
How to access the Program Terms Report (PTR)/Allocations Report and steps a Project Officer should take in reviewing PTRs and the submission timeline.Resource updated 04/11/2023
-
Ending the HIV Epidemic through Innovations in Rapid ART
Review of innovative Rapid ART strategies in diverse settings.Resource updated 03/15/2023
-
Innovation and Resilience: How Ryan White HIV/AIDS Program Recipients Leverage Telehealth during the COVID-19 Pandemic
Recap of changes made in telehealth laws, regulations, and policies and corresponding efforts of healthcare systems, payers, and providers to modify their services to keep clients with HIV engaged in care provided by HRSA's Ryan White HIV/AIDS Program.Resource updated 06/09/2022
-
New Investigational ART Drugs and Strategies
Review of investigational drugs in phase III trials (as of 2021: Islatravir, Lenacapravir, GSK 3640254/aka GSK “254) and how these investigational agents might be used in treatment in the future. Also, review of long-acting injectables.Resource (Conference Presentation) updated 09/14/2023